Regeneron Pharmaceuticals Cash Flow Statement (2009-2026) | REGN

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Cash Flow Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Operating Activities
Net Income (Quarter)	3,098.90M	1,632.20M	2,229.00M	973.50M	852.10M	1,315.70M	1,197.10M	817.80M	968.40M	1,007.80M	1,159.60M	722.00M	1,432.30M	1,340.60M	917.70M	808.70M	1,391.60M	1,460.00M	844.60M	727.20M
Share-based Compensation (Quarter)	145.50M	136.90M	188.40M	166.90M	159.80M	166.30M	232.00M	238.70M	202.00M	203.90M	240.40M	230.10M	223.20M	225.10M	304.40M	255.70M	251.70M	237.00M	249.30M	257.40M
Deferred Taxes (Quarter)	-41.70M	-7.00M	205.90M	225.00M	156.00M	85.70M	279.70M	216.50M	209.30M	125.70M	286.30M	190.40M	118.10M	168.60M	280.20M	139.10M	135.20M	278.60M	232.50M	96.00M
Gains from Investment Securities (Quarter)	-163.90M	642.90M	768.10M	98.80M	-237.10M	-60.70M	-169.00M	-20.60M	133.70M	-130.50M	17.50M	-0.10M	3.00M	772.80M	253.40M	-3.20M	20.90M	-4.80M	519.20M	73.20M
Non-cash Items (Quarter)	-2472.20M	1,781.40M	143.50M	1,128.20M	-287.70M	-686.80M	522.80M	549.80M	54.00M	106.50M	-69.90M	790.50M	-1078.30M	-49.40M	345.10M	236.40M	-247.20M	158.70M	326.10M	351.70M
Cash from Operations (Quarter)	626.70M	3,413.60M	2,372.50M	2,101.70M	564.40M	628.90M	1,719.90M	1,367.60M	1,022.40M	1,114.30M	1,089.70M	1,512.50M	354.00M	1,291.20M	1,262.80M	1,045.10M	1,144.40M	1,618.70M	1,170.70M	1,078.90M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF) (Quarter)	71.10M	73.20M	74.50M	74.30M	74.40M	92.60M	100.10M	99.50M	103.10M	105.40M	113.00M	114.10M	120.70M	121.70M	126.40M	126.90M	135.10M	136.70M	145.00M	123.20M
Change in Working Capital
Change in Receivables (Quarter)	2,825.60M	-1541.00M	584.50M	-1197.50M	322.40M	386.90M	-219.60M	-210.10M	2.70M	463.50M	82.70M	-446.80M	494.10M	388.90M	117.80M	-657.80M	28.20M	80.30M	51.20M	-1.20M
Change in Inventory (Quarter)	-31.30M	109.10M	163.70M	88.60M	240.10M	223.50M	144.30M	46.80M	100.40M	77.20M	47.30M	155.80M	181.80M	164.40M	117.70M	152.30M	42.50M	82.60M	-2.10M	-26.60M
Change in Accured Expenses (Quarter)	458.40M	76.70M	365.70M	-250.40M	-75.30M	-160.30M	347.60M	119.00M	39.70M	578.60M	-138.70M	110.50M	204.60M	194.40M	225.60M	-214.10M	216.40M	759.20M	-24.70M	107.70M
Other Working Capital Changes (Quarter)	-114.80M	-6.40M	311.90M	9.50M	279.00M	-121.20M	-18.70M	-35.90M	44.80M	275.50M	-246.50M	77.90M	526.30M	-252.00M	-124.40M	17.70M	-142.90M	76.60M	423.90M	198.60M
Investing Activities
Capital Expenditures (Quarter)	189.00M	133.20M	154.90M	141.80M	153.60M	142.50M	152.20M	178.20M	-102.80M	391.80M	251.40M	133.90M	17.70M	404.70M	199.60M	229.30M	-50.50M	470.90M	248.70M	230.60M
Change in Intangibles (Quarter)																	155.00M
Acquisitions (Quarter)										51.10M	3.80M				11.50M			3.00M	0.30M
Change in Acquisitions & Divestments (Quarter)	800.80M	680.20M	318.00M	746.30M	1,435.10M	1,831.70M	1,537.40M	1,792.80M	2,268.70M	2,997.80M	2,382.90M	4,132.20M	4,054.50M	4,258.60M	2,582.00M	3,458.30M	2,167.90M	3,365.00M	2,555.00M	2,606.50M
Cash from Investing Activities (Quarter)	125.80M	-2438.80M	-2012.70M	-1705.30M	-413.90M	192.30M	-1857.70M	-235.70M	-2386.90M	-496.30M	-66.20M	-1687.10M	-557.20M	-574.40M	350.60M	647.50M	-1094.00M	-402.90M	220.30M	-428.90M
Financing Activities
Other financing activities (Quarter)														-33.40M		-10.30M
Cash from Financing Activities (Quarter)	-118.20M	385.40M	-906.60M	64.70M	-101.10M	-725.00M	-247.60M	-322.50M	-614.20M	-407.30M	-446.10M	47.10M	-478.10M	-634.00M	-1135.50M	-1089.20M	-1128.20M	-717.90M	-780.10M	-802.20M
Dividend Payments
Dividends Paid - Common (Quarter)																93.80M	92.60M	91.20M	92.70M	97.80M
Additional items
Exchange Rate Effect (Quarter)									-0.40M	-0.20M	0.20M	-0.50M	-0.30M	0.80M	-0.70M	0.60M	0.40M	-0.40M	-0.30M	-0.90M
Change in Cash (Quarter)	634.30M	1,360.20M	-546.80M	461.10M	49.40M	96.20M	-385.40M	809.40M	-1979.10M	210.50M	577.60M	-128.00M	-681.60M	83.60M	477.20M	604.00M	-1077.40M	497.50M	610.60M	-153.10M
Free Cash Flow (Quarter)	437.70M	3,280.40M	2,217.60M	1,959.90M	410.80M	486.40M	1,567.70M	1,189.40M	1,125.20M	722.50M	838.30M	1,378.60M	336.30M	886.50M	1,063.20M	815.80M	1,194.90M	1,147.80M	922.00M	848.30M
Net Cash Flow (Quarter)	634.30M	1,360.20M	-546.80M	461.10M	49.40M	96.20M	-385.40M	809.40M	-1978.70M	210.70M	577.40M	-127.50M	-681.30M	82.80M	477.90M	603.40M	-1077.80M	497.90M	610.90M	-152.20M

Research Tools

Regeneron Pharmaceuticals Cash Flow Statement (2009-2026) | REGN

Create an account

Sign In

Reset Password